A recent real-world study has found that Tirzepatide, a drug primarily approved for type 2 diabetes, can lead to a remarkable weight loss of nearly 13% in individuals without diabetes over a six-month period. The study, published in Diabetes & Metabolism, provides valuable insights into the effectiveness of this medication in real-world settings, where patients are often prescribed it off-label for weight management.
Conducted by researchers from Eli Lilly & Company and Carelon Research, the retrospective study analyzed data from 4,177 patients in the United States who were prescribed Tirzepatide for weight loss. The data, drawn from the Healthcare Integrated Research Database, revealed that 73.8% of participants experienced at least one obesity-related complication, with many remaining on lower doses of Tirzepatide than those used in clinical trials.
While dose escalation was slower in the real world compared to the controlled clinical trials, a significant 12.9% reduction in body weight was observed in a subset of patients who adhered to the medication for at least six months. This result supports Tirzepatide’s potential as an effective treatment for obesity, particularly in individuals with no history of type 2 diabetes.
Notably, the persistence rate among patients was higher than that seen with other GLP-1 receptor agonists, such as semaglutide and liraglutide. However, the study also highlights certain limitations, such as the possibility of selection bias and incomplete data, which may impact the overall findings.
With the prevalence of obesity rising globally, particularly in the United States, the study emphasizes the urgent need for effective weight management solutions. Tirzepatide’s promising results could provide a significant tool in combating obesity and its related health complications, though further research is needed to fully assess its long-term impact.
This study also underscores the growing interest in using medications like Tirzepatide beyond their original indications, offering hope for those struggling with obesity, even without diabetes.
Related topics:
Improving Sleep Health May Prevent Progression of Gestational Diabetes to Type 2 Diabetes
TTSH and Buzud Develop AI Tool for Accurate Insulin Dosage in Diabetics
Racial Disparities in Gestational Diabetes Diagnosis Raise Concerns
